Background
==========

Treatments for systemic lupus erythematosus (SLE) include corticosteroids (CS), antimalarials, nonsteroidal anti-inflammatory drugs, cytotoxic agents, and immunosuppressive/immunomodulatory agents. We examined treatment patterns in newly diagnosed SLE patients from a multipayer US claims database.

Methods
=======

This study (GSK HO-13-13054) retrospectively followed incident SLE patients\' treatment for 4 years in the MarketScan commercial claims database. The earliest medical claim date with SLE diagnosis (ICD-9 code 710.0x; 1 January 2002 to 31 March 2008) was the index date. Patients were ≥18 years at index, had continuous medical and pharmacy benefits for 12 months pre index without SLE diagnosis and 48 months post index, with ≥1 SLE-related inpatient claim or ≥2 office or emergency room visits with SLE diagnosis ≥30 days apart within 12 months post index. A specialist must have made ≥1 SLE diagnosis at index or within 12 months post index. Results were stratified by provider type (primary care physician (PCP)/specialist). A disjoint k-means cluster analysis identified treatment pathways using annual prescription numbers for CS, hydroxychloroquine (HCQ), mycophenolate mofetil, azathioprine, and methotrexate as input variables.

Results
=======

The study identified 2,086 newly diagnosed SLE patients (mean age: 47.2 years; female: 91%). In the 4 years post index, 1,031 (49.4%) patients were not actively treated (\<0.05 prescriptions/year). Of the 219 (10.5%) patients who primarily received CS, 42 had persistently high numbers of prescriptions (\~1/month), and 177 received 4.9 (mean) prescriptions in Year 1, decreasing in Years 2 to 4. Three subgroups emerged within the 606 (29.1%) patients who primarily received HCQ: persistent high number of prescriptions (\~1/month), persistent moderate number of prescriptions (3.2 to 4.1/year), and poor adherence (Year 1, 8.7 prescriptions; Years 2 to 4, decreasing prescriptions). Both CS and HCQ were received by 138 (6.6%) patients; 56 had high numbers of prescriptions (Years 1 to 4); 82 showed progressively decreasing prescriptions. Fifty-four (2.6%) and 38 (1.8%) patients had moderate numbers of prescriptions for methotrexate (5.4 to 8.4/year) and azathioprine (5.7 to 7.5/year), respectively, with some CS and HCQ prescriptions. Treatment patterns differed in patients seen by specialists versus PCPs (*P*\< 0.0001). Specialist-treated patients had a lower no-treatment rate than PCP-treated patients, and higher rates in active treatment clusters (Table [1](#T1){ref-type="table"}).

###### 

Longitudinal treatment patterns according to primary treatment by specialist or PCP

  Cluster   Interpretation                                                                          Treated primarily by specialists^a^   Treated primarily by PCPs^a^          
  --------- --------------------------------------------------------------------------------------- ------------------------------------- ------------------------------ ------ -------
  1         Not actively treated throughout (\<0.05 (mean) annual prescriptions)                    216                                   26.2                           815    64.6
  2         CS only: high number of prescriptions (chronic use)                                     29                                    3.5                            13     1.0
  3         CS only: moderate number of prescriptions with slow reduction                           85                                    10.3                           92     7.3
  4         HCQ only: high number of prescriptions (chronic use)                                    102                                   12.4                           56     4.4
  5         HCQ only: moderate number of prescriptions (chronic use)                                136                                   16.5                           134    10.6
  6         HCQ only: poor adherence                                                                111                                   13.5                           67     5.3
  7         CS plus HCQ: high number of prescriptions (chronic use)                                 32                                    3.9                            24     1.9
  8         CS plus HCQ: poor adherence                                                             51                                    6.2                            31     2.5
  9         Methotrexate: moderate number of prescriptions plus some prescriptions for CS and HCQ   34                                    4.1                            20     1.6
  10        Azathioprine: moderate number of prescriptions plus some prescriptions for CS and HCQ   28                                    3.4                            10     0.8
  Total                                                                                             824                                   100.0                          1262   100.0

^a^Patients who visited a specialist (including a rheumatologist, dermatologist, nephrologist, ophthalmologist, or oncologist) in \>50% of SLE-related office visits were defined as primarily seen by specialists. Patients who visited PCPs in \>50% of SLE-related office visits were defined as primarily seen by PCPs. The difference in treatment patterns between the two groups was statistically significant (*P*\< 0.0001).

Conclusions
===========

Treatment patterns were observed among SLE patients using medical resources. In the 4 years post diagnosis: \~50% of patients were not actively treated; 50% received CS, HCQ, and immunosuppressants with differing combinations, intensities, and adherence levels. Specialists provided more intensive treatment than PCPs.
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